Optimizing antiepileptic drug therapy in the elderly

Annals of Pharmacotherapy

Volumn 39, Issue 11, 2005, Pages 1852-1860

  Garnett, William R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiepileptic drugs; Elderly

Indexed keywords

AMIODARONE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CIMETIDINE; CLARITHROMYCIN; DEXAMETHASONE; ERYTHROMYCIN; ETIRACETAM; FELBAMATE; FLUCONAZOLE; FLUINDOSTATIN; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HYPERICUM PERFORATUM EXTRACT; ISONIAZID; LAMOTRIGINE; LOSARTAN; MIDAZOLAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RIFAMPICIN; TIAGABINE; TICLOPIDINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; ZONISAMIDE;

AGE DISTRIBUTION; AGED; BEHAVIOR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITION; COGNITIVE DEFECT; COMPLEX PARTIAL SEIZURE; DIAGNOSTIC ACCURACY; DRUG APPROVAL; DRUG METABOLISM; DRUG TOLERABILITY; ELDERLY CARE; GENERALIZED EPILEPSY; GRAND MAL EPILEPSY; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; METABOLIC ACIDOSIS; NEPHROLITHIASIS; NEUROTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANTICONVULSANTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG MONITORING; HUMANS; SEIZURES;

EID: 27344445337     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E683     Document Type: Review

References (78)

1. Hauser WA. Epidemiology of seizures in the elderly. In: Rowan AJ, Ramsay RE, eds. Seizures and epilepsy in the elderly. Boston: Butterworth-Heinemann, 1997:7-20.
2. Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet 2000;355:1441-6.
3. Eisenschenk S, Gilmore R. Adult-onset seizures: clinical solutions to a challenging patient work-up. Geriatrics 1999;54:18-28.
4. Singer RB. Incidence of seizures after traumatic brain injury-a 50-year population survey. J Insur Med 2001;33:42-5.
5. Bladin CF, Alexandrov AV, Bellavance A, Bornstein N, Chambers B, Cote R, et al. Seizures after stroke: a prospective multicenter study. Arch Neurol 2000;57:1617-22.
6. Annegers JF, Coan SP. The risks of epilepsy after traumatic brain injury. Seizure 2000;9:453-7.
7. Tallis R, Boon P, Perucca E, Stephen L. Epilepsy in elderly people: management issues. Epileptic Disord 2002;4(suppl 2):S33-9.
8. Hiyoshi T, Yagi K. Epilepsy in the elderly. Epilepsia 2000;41(suppl 9):31-5.
9. Leppik IE, Cloyd JC. General principles: epilepsy in the elderly. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs. 5th ed. Lippincott Williams & Wilkins, 2002:149-58.
10. Hughes JR, Zialcita ML. EEG in the elderly: seizures vs syncope. Clin Electroencephalogr 2000;31:131-7.
11. Zaidi A, Clough P, Cooper P, Scheepers B, Fitzpatrick AP. Misdiagnosis of epilepsy: many seizure-like attacks have a cardiovascular cause. J Am Coll Cardiol 2000;36:181-4.
12. DeToledo JC. Changing presentation of seizures with aging: clinical and etiological factors. Gerontology 1999;45:329-35.
13. Tuniper P. The altered presentation of seizures in the elderly. In: Rowan AJ, Ramsay RE, eds. Seizures and epilepsy in the elderly. Boston: Butterworth-Heinemann, 1997:123-30.
14. Siren JI. Epilepsy in older adults: causes, consequences, and treatment. J Am Geriatr Soc 1998;46:1291-301.
15. Gidal BE, Garnett WR, Graves N. Epilepsy. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 5th ed. New York: McGraw-Hill, 2002:1031-59.
16. Faught E. Epidemiology and drug treatment of epilepsy in elderly people. Drugs Aging 1999;15:255-69.
17. Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003;60(suppl 4):S2-12.
18. French JA, Schachter S. A workshop on antiepileptic drug monotherapy indications. Epilepsia 2002;43(suppl 10):3-27.
19. Ramsay GE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology 2004;62(suppl 2):S24-9.
20. Willmore LJ. Choice and use of newer anticonvulsant drugs in older patients. Drugs Aging 2000;17:441-52.
21. Rowan AJ. Management of seizures in the elderly. Pharmacotherapy 2000;20(8 pt 2):178S-84S.
22. Lackner TE. Strategies for optimizing antiepileptic drug therapy in elderly people. Pharmacotherapy 2002;22:329-64.
23. Rowan AJ. Fundamentals of drug management of epilepsy in the older patient. Geriatrics 2002;57:33-7.
24. Bourdet SV, Gidal BE, Alldredge BK. Pharmacologic management of epilepsy in the elderly. J Am Pharm Assoc Wash 2001;41:421-36.
25. Faught E. Pharmacokinetic considerations in prescribing antiepileptic drugs. Epilepsia 2001;42(suppl 4):19-23.
26. Leppik IE, Birnbaum A. Epilepsy in the elderly. Semin Neurol 2002;22:309-20.
27. Lindi NA. Managing interactions: antibiotics and antiepileptic drugs. Profile Seizure Manage 2003;2(4):5-10.
28. Cloyd JC, Remmel RP. Antiepileptic drug pharmacokinetics and interactions: impact on treatment of epilepsy. Pharmacotherapy 2000;20(8 pt 2):139S-51S.
29. Greenblatt DJ, Shader RI, Harmatz JS. Implications of altered drug disposition in the elderly: studies of benzodiazepines. J Clin Pharmacol 1989;29:866-72.
30. Albrecht S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, Schwilden H. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 1999;65:630-9.
31. Cameron H, Macphee G. Anticonvulsant therapy in the elderly-a need for placebo controlled trials. Epilepsy Res 1995;21:149-57.
32. Garnett WR, Barr WH. Geriatric pharmacokinetics. SCOPE Monograph Series. Kalamazoo, MI: Upjohn, 1984.
33. Anderson DG. A mechanistic approach to antiepileptic drug interactions, Ann Pharmacother 1998;32:554-63. DOI 10.1345/aph.17332
34. Patsalos PN, Froscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43:365-85.
35. MacKichan JJ. Pharmacokinetic consequences of drug displacement from blood and tissue proteins. Clin Pharmacokinet 1984;9(suppl 1):32-41.
36. Besag FM, Berry DJ, Pool F, Newberry JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998;39:183-7.
37. Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res 2002;48:217-9.
38. Garnett WR. Antiepileptic drug treatment: outcomes and adherence. Pharmacotherapy 2000;20(8 pt 2):191S-9S.
39. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Brown TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51.
40. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992;327:765-71.
41. Privitera M, Ficker DM. Assessment of adverse events and quality of life in epilepsy: design of a new community-based trial. Epilepsy Behav 2004;5:841-6.
42. Ramsay RE, Rowan AJ, Pryor FM, Collins JF, DVA Coop Study Group 428. Treatment of seizures in the elderly: final analysis from DVA Cooperative Study 428 (abstract). Epilepsia 2003;44(suppl 9):170.
43. Wilner AN. New AEDs offer improved seizure control and tolerability in elderly with new-onset seizures. Neurol Rev October 2003;11(10). www.neurologyreviews.com/oct03/nr_oct03_seizures.html (accessed 2004 June 18).
44. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999;37:81-7.
45. Nieto-Barrera M, Brozmanova M, Capovilla G, Christe W, Pedersen B, Kane K, et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res 2001;46:145-55.
46. Giorgi L, Gomez G, O'Neill F, Hammer AE, Risner M. The tolerability of lamotrigine in elderly patients with epilepsy. Drugs Aging 2001;18:621-30.
47. Meador KJ. Current discoveries on the cognitive effects of antiepileptic drugs. Pharmacotherapy 2000;20(8 pt 2):185S-90S.
48. Loring DW, Meador KJ. Cognitive and behavioral effects of epilepsy treatment. Epilepsia 2001;42(suppl 8):24-32.
49. Aldenkamp AP, Krom MD, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003;44(suppl 4):21-9.
50. Mervaala E, Koivista K, Hanninen T, Paakkonen A, Kononen M, Partanen J, et al. Electrophysiological and neuropsychological profiles of lamotrigine in young and age-associated memory impairment (AAMI) subjects (abstract). Neurology 1995;45(suppl 4):A259.
51. Aldenkamp AP, Baker G. A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav 2001;2:85-91.
52. Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004;62:2051-7.
53. Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy Behav 2004;5(suppl 2):S24-9.
54. Karceski S, Morrell M, Carpenter D. The Expert Consensus Guideline Series: treatment of epilepsy. Epilepsy Behav 2001;2(suppl):A1-50.
55. Anderson GD, Pak C, Doane KW, Griffy KG, Temkin NR, Wilensky AJ, et al. Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. Ann Pharmacother 1997;31:279-84.
56. Bauer LA, Bloudin RA. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther 1982;31:301-4.
57. Hockings N, Pall A, Moody J, Davidson AV, Davidson DL. The effects of age on carbamazepine pharmacokinetics and adverse effects. Br J Clin Pharmacol 1986;22:725-8.
58. Battino D, Croci D, Rossini A, Messina S, Mamoli D, Perucca E. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. Epilepsia 2003;44:923-9.
59. Jiao Z, Zhong MK, Shi XJ, Hu M, Zhang JH. Population pharmacokinetics of carbamazepine in Chinese epilepsy patients. Ther Drug Monit 2003;25:279-86.
60. Lahr MB. Hyponatremia during carbamazepine therapy. Clin Pharmacol Ther 1985;37:693-6.
61. Bauer LA, Davis R, Wilensky A, Raisys V, Levy RH. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther 1985;37:697-700.
62. Perucca E, Grimaldi R, Gatti G, Pirracchio S, Crema F, Frigo GM. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 1984;17:665-9.
63. Gidal BE, Collins DM, Beinlich BR. Apparent valproic acid neurotoxicity in a hypoalbuminemic patient. Ann Pharmacother 1993;27:32-5.
64. Stephen LJ. Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging 2003;20:141-52.
65. Richens A, Banfield CR, Salfi M, Nomeir A, Lin CC, Jensen P, et al. Single and multiple dose pharmacokinetics of felbamate in the elderly. Br J Clin Pharmacol 1997;44:129-34.
66. Boyd RA, Turck D, Abel RB, Sedman AJ, Bockbrader HN. Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia 1999;40:474-9.
67. Posner J, Holdich T, Chrome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1991;1:121-8.
68. Package insert. Lamictal (lamotrigine). Research Triangle Park, NC: GlaxoSmithKline, 2004.
69. Gisclon LG, Riffittis JM, Sica DA, Gehr T, Ruddlex J. The pharmacokinetics of topiramate in subjects with renal impairment as compared to matched subjects with normal renal function (abstract). Pharm Res 1993;10(suppl):S397.
70. Christensen J, Poulsen JH, Dam M. Effects of age, gender, body weight, and dosing profile on steady state trough concentrations of topiramate (abstract). Epilepsia 1999;40(suppl 7):S105.
71. Snel S, Jansen JA, Mengel HB, Richens A, Larsen S. The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy. J Clin Pharmacol 1997;37:1015-20.
72. Pedersen B. Epilepsy in the elderly: the use of tiagabine. Epilepsia 2001;42(suppl 3):52-4.
73. Patsalos PN. The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol 2003;25:123-9.
74. Cramer JA, Leppik IE, Rue KD, Edrich P, Kramer G. Tolerability of levetiracetam in elderly patients with CNS disorders. Epilepsy Res 2003;56:135-45.
75. van Heiningen PN, Eve MD, Oosterhuis B, Jonkman JH, de Bruin H, Hulsman JA, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991;50:410-9.
76. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994;35:181-8.
77. Kutluay E, McCague K, D'Souza J, Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 2003;4:175-80.
78. Wallace J, Shellenberger K, Groves L. Pharmacokinetics of zonisamide in young and elderly subjects. Epilepsia 1998;39:190-1.